SEATTLE, WA -- (MARKET WIRE) -- February 28, 2007 -- Targeted Genetics Corporation (NASDAQ: TGEN) today announced that Dr. Jan van Lunzen, Medical Director, University Medical Center, Hamburg Eppendorf, Germany, presented updated Phase I data from a study of tgAAC09 in healthy volunteers not infected with HIV in a poster presentation at the 14th Conference on Retroviruses and Opportunistic Infections in Los Angeles. The tgAAC09 vaccine candidate utilizes an adeno-associated virus (AAV) vector to deliver genes encoding HIV proteins and is designed to stimulate an immune response against HIV. Targeted Genetics, the International AIDS Vaccine Initiative (IAVI) and researchers at Columbus Children’s Research Center and Children’s Hospital of Philadelphia are collaborating on the development of tgAAC09 and other AAV-based HIV vaccines.
